Necrotizing Fasciitis Treatment Market Size, Share, and Industry Analysis By Type (Type I (Polymicrobial), Type II (Monomicrobial), and Type III (Gas Gangrene)), By Drug (Metronidazole, Vancomycin, Imipenem, Piperacillin, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

The global necrotizing fasciitis treatment market is witnessing significant growth due to the increasing demand for treatment and awareness regarding the disease management. Moreover, factors such as high obesity rates, alcohol use disorder, cancers, and cuts in the skin or mucous membranes, including those made during surgical procedures, are also expected to increase the risk of developing necrotizing fasciitis among the global population. This is expected to boost the demand for treatment, thereby driving market growth over the coming years.

• For instance, as of August 2024, the World Heart Federation reports that around 2.3 billion children and adults are living with overweight and obesity. The number could reach 2.7 billion by 2025 if the same trend continues.

Necrotizing Fasciitis Treatment Market Driver

Increasing Incidence of Necrotizing Fasciitis Boosts Market Growth

The rising incidence of necrotizing fasciitis, commonly referred to as flesh-eating disease, may lead to life-threatening conditions affecting the skin, muscles, and soft tissue and may cause patches of tissue to die if left untreated. Such a quick and aggressive spread of this disease is expected to boost the treatment demand and propel market expansion over the coming years.

• For instance, in May 2024, an article published by the Cleveland Clinic stated that the number of necrotizing fasciitis cases was estimated to be 0.3 to 15 per 100,000 people.

The U.S. accounted for an estimated 770 necrotizing fasciitis cases caused due to group A streptococcus in 2023.

Necrotizing Fasciitis Treatment Market Restraint

Antimicrobial Resistance May Hamper Market Growth

The presence of antibiotic-resistant strains of bacteria can hinder the effectiveness of antibiotic treatment. Broad-spectrum antibiotics are typically used initially. However, the emergence of resistant strains can complicate the treatment regimens, limiting the use of antibiotics. Such a scenario is projected to limit the market growth during the forecast period.

• For instance, as per an article published by MDPI in October 2022, ceftriaxone resistance has been increasing over the past decade and the most reported strains are the Klebsiella species, Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii, Salmonella Typhi, and Staphylococcus aureus.

Necrotizing Fasciitis Treatment Market Opportunity

Research and Development for Novel Antibiotics to Foster Market Growth

In the recent years, there has been a surge in research and development activities for the introduction of novel compounds to treat necrotizing fasciitis. In response, several research organizations and pharmaceutical companies are increasing investments in research and development activities for necrotizing fasciitis drugs, which is expected to provide beneficial opportunities for market growth.

• For instance, in July 2024, researchers at the Washington University School of Medicine in St. Louis developed a new compound that effectively clears bacterial infections, including those that can result in flesh-eating illnesses such as necrotizing fasciitis. This compound could be the first of an entirely new class of antibiotics, which is expected to help clinicians provide more effective treatments.

Segmentation

By Type	By Drug	By Route of Administration	By Distribution Channel	By Geography
Type I (Polymicrobial) Type II (Monomicrobial) Type III (Gas Gangrene)	Metronidazole Vancomycin Imipenem  Piperacillin Others	Oral Parenteral	Hospital Pharmacies Drug Stores & Retail Pharmacies Online Pharmacies	North America (U.S. and Canada) Europe (U.K., Germany, France, Spain, Italy, Scandinavia, and the Rest of Europe) Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific) Latin America (Brazil, Mexico, and the Rest of Latin America) Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)

Key Insights

The report covers the following key insights:

• Prevalence of Necrotizing Fasciitis, By Key Countries, 2023


• Pipeline Analysis, By Key Players


• Guidelines for Necrotizing Fasciitis, By Key Countries/Region


• New Product Launches, By Key Players


• Key Industry Developments (Mergers, Acquisitions, and Partnerships)


• Impact of COVID-19 on the Market

Analysis by Type

Based on type, the market for necrotizing fasciitis treatment is fragmented into Type I (polymicrobial), Type II (monomicrobial), and Type III (gas gangrene).

The type II (monomicrobial) segment is expected to hold a major share of the global market. This growth can be attributed to the widespread infection of type II necrotizing fasciitis across the globe as it is the most common type of disease compared to type I and type III and affects all the age groups. Such a scenario is projected to stimulate key players to increase the availability of antibiotic drugs, driving the segmental growth over the coming years.

• For instance, as of August 2024, an article published on DermNet states that type II necrotizing fasciitis, commonly referred to as a flesh-eating disease, and affects all age groups, including healthy people.

Analysis by Drug

By drug, the market is categorized into metronidazole, vancomycin, imipenem, piperacillin, and others.

The vancomycin segment is projected to account for a substantial market share over the coming years. The segment growth can be attributed to the preference for vancomycin in combination with other drugs if methicillin-resistant Staphylococcus aureus (MRSA) is suspected. This is expected to boost the demand for vancomycin over the forthcoming years.

• For instance, in 2021, the WHO Expert Committee on Selection and Use of Essential Medicines stated that MRSA resistance tends to be covered by vancomycin when used in combination with other drugs.

Analysis by Route of Administration

By route of administration, the market for necrotizing fasciitis treatment is segmented into oral and parenteral.

The parenteral segment is anticipated to hold a significant market share over the forthcoming years. This growth can be attributed to the high preference for intravenous (IV) drugs for necrotizing fasciitis due to the need for rapid and effective delivery of broad-spectrum antibiotics, which are critical in managing this life-threatening infection. In consideration of this, various antimicrobial therapies using IV drugs are prescribed for this condition.

• For instance, according to an article published by the National Center for Biotechnology Information (NCBI) in February 2023, the antimicrobial therapy for necrotizing fasciitis includes meropenem 1 g IV every 8 hours and vancomycin 15 to 20 mg/kg/dose every 8 to 12 hours and clindamycin 600 mg to 900 mg four times per day.

Analysis by Distribution Channel

By distribution channel, the market for necrotizing fasciitis treatment is fragmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The online pharmacies segment is projected to grow substantially due to the preferential shift of patients purchasing antibiotics from online pharmacies. This shift can be attributed to the development of e-commerce and discounts offered by online pharmacies for necrotizing fasciitis drugs. Such a scenario is expected to accelerate the segment growth during the forecast period.

• For instance, as per an article published by Frontiers Media S.A. in November 2021, the online sales of antibiotics increased with the development of electronic commerce.

Regional Analysis

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for the largest share of the global necrotizing fasciitis treatment market in 2023. The region’s growth is attributed to the rising diagnoses of necrotizing fasciitis. Such a scenario is driving the demand for necrotizing fasciitis treatment, which is anticipated to boost the market growth.

• For instance, according to an article published by WebMD LLC in November 2023, around 700 to 1,150 cases of necrotizing fasciitis are diagnosed in the U.S. annually.

Europe is the second-largest market based on the demand for necrotizing fasciitis treatments. The growth is due to the existence of key players with strong distribution networks for necrotizing fasciitis drugs, contributing to their penetration in the region.

The Asia Pacific market is expected to grow at a substantial CAGR during the forecast period. The region’s growth can be attributed to the rising geriatric population and patients with diabetes mellitus, who are more susceptible to type I necrotizing fasciitis. This is expected to fuel the demand for metronidazole, clindamycin, or carbapenems (imipenem) as they are effective drugs in treating this type of necrotizing fasciitis.

Key Players Covered

The global necrotizing fasciitis treatment market is fragmented, with a large number of companies offering various necrotizing fasciitis drugs.

The report includes the profiles of the following key players:

• Pfizer Inc. (U.S.)


• Cadila Pharmaceuticals (India)


• Sun Pharmaceutical Industries Ltd (India)


• GSK plc (U.K.)


• Bristol-Myers Squibb Company (U.S.)


• Teva Pharmaceutical Industries Ltd. (Israel)

Key Industry Developments

• In June 2024, Eli Lilly and Company collaborated with OpenAI to discover novel medicines to treat drug-resistant bacteria.


• In December 2020, Atox Bio announced that the U.S. FDA accepted to file the New Drug Application (NDA) for reltecimod with a Prescription Drug User Fee Act (PDUFA) to treat suspected organ dysfunction or failure in patients with necrotizing soft tissue infection (NSTI).